In This Section
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
The new AUC for somatostatin receptor PET imaging addresses several clinical scenarios for neuroendocrine tumors. To improve utilization and guide providers to use somatostatin receptor PET imaging for neuroendocrine tumors in a more appropriate way, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM), the European Neuroendocrine Tumor Society (ENETS), the American Gastroenterological Association (AGA), the American Society of Clinical Oncology (ASCO), the American College of Radiology (ACR), the National Comprehensive Cancer Network (NCCN), the American Joint Committee on Cancer (AJCC), the North American Neuroendocrine Tumor Society (NANETS), the National Cancer Institute (NCI), the Endocrine Society, the American Association of Endocrine Surgeons (AAES), and the Society of Surgical Oncology (SSO) have collaboratively developed criteria for the appropriate use of this imaging technology to aid in the diagnosis of people with neuroendocrine tumors.
SNMMI assembled an autonomous Somatostatin Receptor PET Imaging in Neuroendocrine Tumors Workgroup consisting of experts in the field of nuclear medicine including radiologists, pharmacologists, endocrinologists, surgeons, oncologists and patient advocates to review the scientific literature and develop consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center (EPC) conducted a systematic review of existing evidence based on the scope and parameters the Somatostatin Receptor PET Imaging in Neuroendocrine Tumors Workgroup put together, which they used to make their recommendations for clinical use.
To view the development process, please click the following link: SNMMI AUC Development Process.